<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="24"><SearchResults><Trial Id="93718"><Indications><Indication>Constipation</Indication></Indications><CompaniesSponsor><Company>Solvay Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2006-06-30T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00160290</Identifier><Identifier>S105.4.106</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Plantago ovata alone</Intervention><Intervention>lactulose alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>97</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this study was to demonstrate that lactulose acts as a stool softener, relieving the pain at defecation, improving the number of defecations and regulating the colonic transit time in patients suffering of hemorrhoids or anal fissure; to compare efficacy and quality of life in patients treated either with lactulose or plantago ovata.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures</TitleDisplay><PrimaryCompletionDate type="Actual">2006-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Global Clinical Director Solvay</Name></ContactNames></Trial><Trial Id="77335"><Indications><Indication>Growth hormone deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Growth hormone ligand</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cloning technology</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-01-27T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2005-05-31T00:00:00Z</DateStart><Identifiers><Identifier>FAYDS</Identifier><Identifier>FER-SOM-2004-01</Identifier><Identifier>NCT01351818</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>somatropin, Horizon Pharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>62</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the influence of exogenous GH (growth hormone) ( somatropin ) administration on adipocyte endocrine function (leptin, adiponectin, and resistin) and on ghrelin secretion in children with delayed growth due to GH deficiency. The hypothesis of this study was that the hormones produced by the adipocyte (leptin, adiponectin, and resistin) and ghrelin may exert a certain control on production of GH and insulin-like growth factor-1 (IGF-1), and GH may in turn</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of height</EndpointIndex><EndpointIndex>Hypopituitarism - Anthropometric Assessments - Assessment of weight</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Adipocytes Endocrine Function - Assessment of resistin</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Hormone Levels - Assessment of ghrelin levels</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Hormone Levels - Assessment of leptin</EndpointIndex><EndpointIndex>Hypopituitarism - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of adiponectin</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>FAYDS: Adipocyte Function and Somatropin Deficiency</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypopituitarism - Subjects with Growth hormone (GH) Deficiency</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> Appetite regulating hormone </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Resistin </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="68274"><Indications><Indication>Non-insulin dependent diabetes</Indication><Indication>Renal insufficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium glucose transporter-2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Boehringer Ingelheim Corp</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Malaysia</Country><Country>Philippines</Country><Country>Hong Kong</Country><Country>France</Country><Country>Canada</Country><Country>Netherlands</Country><Country>Spain</Country><Country>Slovakia</Country><Country>India</Country><Country>Portugal</Country><Country>US</Country><Country>Russian Federation</Country><Country>UK</Country><Country>South Africa</Country></Countries><DateChangeLast>2018-11-14T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1245.36</Identifier><Identifier>2009-016179-31</Identifier><Identifier>EMPA-REG RENAL</Identifier><Identifier>NCT01164501</Identifier><Identifier>NMRR-10-719-6095</Identifier></Identifiers><IndicationsAdverse><Indication>Bone injury</Indication><Indication>Hypoglycemia</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>empagliflozin (mild RI) alone</Intervention><Intervention>empagliflozin (moderate RI) alone</Intervention><Intervention>empagliflozin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>741</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to evaluate the efficacy and safety of the BI-10773 in type 2 diabetic patients with renal impairment (RI) in order to provide these data for approval for BI-10773 as an antidiabetic agent by regulatory authorities. By 2012, the study was completed in 741 patients [ 1354812 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of abdominal circumference</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Time to HbA1c response [Time to HbA1c target]</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EMPA-REG RENAL: Efficacy and Safety of Empagliflozin (BI-10773) in Patients With Type 2 Diabetes and Renal Impairment</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>113</NumberOfSites><ContactNames><Name>Azmira Khalid</Name><Name>Boehringer Ingelheim</Name><Name>Samantha Hew</Name><Name>Zaiton Saliman</Name></ContactNames></Trial><Trial Id="66332"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Interferon alpha 5 ligand</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha 5 ligand</Action><Action>Interferon alpha ligand modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Systemic dermatological antiviral product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Digna Biotech SL</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-012924-10</Identifier><Identifier>NAHE001-CHC-01</Identifier><Identifier>NCT01121731</Identifier></Identifiers><InterventionsControlDisplay><Intervention>NAHE-001 alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>interferon alfa-2b alone</Intervention><Intervention>NAHE-001 plus interferon alfa-2b</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study is to determine if 3 MIU of interferon-alpha 5 in monotherapy, and 1.5 MIU of interferon-alpha 5 combined with 1.5 MIU of interferon-alpha 2b (Intron A), are safe dose levels as well as to investigate the antiviral efficacy and pharmacodynamics (PD) of such doses and drugs in treatment-experienced HCV patients with genotype 1 chronic infection, after 29 days of treatment. The study is also intended to determine pharmacokinetics (PK) of the safe dose achieved of interferon-alpha</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase I/II Clinical Trial With Interferon Alpha 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Jesús Prieto</Name></ContactNames></Trial><Trial Id="5912"><Indications><Indication>Essential hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II AT-1 receptor antagonist</Action><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Diuretic agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Daiichi Sankyo Europe GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Daiichi Sankyo Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Ukraine</Country><Country>Germany</Country><Country>France</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2018-08-27T00:00:00Z</DateChangeLast><DateEnd>2008-05-31T00:00:00Z</DateEnd><DateStart>2007-02-28T00:00:00Z</DateStart><Identifiers><Identifier>CS866CM-B-E301</Identifier><Identifier>NCT00430508</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo alone</Intervention><Intervention>olmesartan medoxomil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>972</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study aimed to evaluate the effect of two different dosages of the combination of olmesartan + hydrochlorothiazide on blood pressure reduction in patients with moderate or severe high blood pressure.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - BP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Trough SBP</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 3 (JNC 6) hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>54</NumberOfSites><ContactNames><Name>Professor Lars Christian Rump, M.D.</Name></ContactNames></Trial><Trial Id="43050"><Indications><Indication>Metastatic head and neck cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateEnd>2006-03-31T00:00:00Z</DateEnd><DateStart>2003-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1839IL/0504</Identifier><Identifier>NCT00242762</Identifier></Identifiers><IndicationsAdverse><Indication>Alopecia</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Diarrhea</Indication><Indication>Dysphagia</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Leukopenia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including ZD-1839 + docetaxel + cisplatin , cisplatin , docetaxel , gefitinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to evaluate the activity of the combination ZD-1839 , docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by estimating the objective response rate (complete response [CR] and partial response [PR]) at study closure.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of chemotherapy induced nausea and vomiting</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Survival - Assessment of median survival</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ZD-1839 (Iressa) in Combination With Docetaxel And Cisplatin in Subjects With Metastatic Head And Neck Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with glottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with subglottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer - Subjects with supraglottic laryngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Oral Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with hypopharyngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Pharyngeal Cancer - Subjects with oropharyngeal cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Relapsed/Recurrent Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage IV Head and Neck Cancer - Subjects with TNM stage IVc HNC</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>AstraZeneca Spain Medical Director, MD</Name></ContactNames></Trial><Trial Id="42636"><Indications><Indication>Head and neck tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>Czech Republic</Country><Country>Lithuania</Country><Country>South Africa</Country><Country>Canada</Country><Country>Malaysia</Country><Country>Latvia</Country><Country>Thailand</Country><Country>Netherlands</Country><Country>Estonia</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Greece</Country><Country>Australia</Country><Country>US</Country><Country>India</Country><Country>Italy</Country><Country>Israel</Country><Country>Argentina</Country><Country>Norway</Country><Country>Belgium</Country><Country>Slovenia</Country><Country>Sweden</Country><Country>UK</Country><Country>Croatia</Country></Countries><DateChangeLast>2018-06-18T00:00:00Z</DateChangeLast><DateEnd>2007-09-30T00:00:00Z</DateEnd><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1839IL/0704</Identifier><Identifier>2004-002662-38</Identifier><Identifier>D7919C00704</Identifier><Identifier>IMEX</Identifier><Identifier>NCT00072878</Identifier><Identifier>NCT00206219</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication><Indication>Stomatitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>methotrexate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>gefitinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>477</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to compare ZD-1839 ( gefitinib 250 and 500 mg) versus methotrexate in head and neck cancer in terms of overall survival. Secondary objectives : To compare ZD-1839 (250 mg and 500 mg) versus methotrexate in terms of symptom improvement, overall objective tumor response (CR + PR) using RECIST criteria, safety and tolerability. To assess quality of life of patients treated with ZD-1839 (250 and 500 mg) versus methotrexate.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Chemotherapy Induced Toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IMEX: Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)</TitleDisplay><PatientSegmentTerms><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor </BiomarkerName><BiomarkerName> HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>106</NumberOfSites><ContactNames><Name>AstraZeneca Iressa Medical Science Director, MD</Name></ContactNames></Trial><Trial Id="39080"><Indications><Indication>Postmenopausal osteoporosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Bone resorption inhibitor</Action><Action>Osteoclast inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Warner Chilcott plc</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Spain</Country><Country>Lebanon</Country><Country>Finland</Country><Country>US</Country><Country>Canada</Country><Country>Brazil</Country><Country>France</Country><Country>Belgium</Country><Country>Estonia</Country><Country>Australia</Country><Country>Hungary</Country><Country>Argentina</Country><Country>Norway</Country></Countries><DateChangeLast>2018-11-29T00:00:00Z</DateChangeLast><DateEnd>2008-04-30T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-002785-10</Identifier><Identifier>2005032</Identifier><Identifier>EFC6062 AND HMRF004M/3001</Identifier><Identifier>MERIT-OP</Identifier><Identifier>NCT00247273</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Constipation</Indication><Indication>Diarrhea</Indication><Indication>Influenza virus infection</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>risedronate sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1294</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily [ 831623 ], [ 867166 ], [ 867460 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Menopause - Assessment of Biomarkers - Assessment of bone markers</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment of bone fracture</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked C-terminal telopeptide(CTX)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked N-telopeptide</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Fractures - Assessment of vertebral fractures</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Assessment of bone specific alkaline phosphatase</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Serum total alkaline phosphatase (ALP)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Urine Type-I Collagen N-telopeptide/Creatinine (NTX / Cr)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MERIT-OP: A Study of Monthly Risedronate for Osteoporosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Menopause - Subjects with Premature Menopause - Subjects with surgical menopause</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment><PatientSegment>Osteoporosis - Subjects at risk of developing disease - Women at risk of developing osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Postmenopausal Osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Primary Osteoporosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase, tissue-nonspecific isozyme </BiomarkerName><BiomarkerName> Collagen type I trimeric cross-linked peptide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>49</NumberOfSites><ContactNames><Name>Sal Bartelmo</Name></ContactNames></Trial><Trial Id="38820"><Indications><Indication>Postmenopausal osteoporosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bone resorption inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>Spain</Country><Country>Netherlands</Country><Country>US</Country></Countries><DateChangeLast>2013-09-14T00:00:00Z</DateChangeLast><DateEnd>2003-09-30T00:00:00Z</DateEnd><DateStart>2003-04-30T00:00:00Z</DateStart><Identifiers><Identifier>8149</Identifier><Identifier>H3S-MC-GGLF</Identifier><Identifier>NCT00532428</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>raloxifene alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>31</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista ( CORE ) Study.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Menopause - Assessment of Biomarkers - Assessment of bone markers</EndpointIndex><EndpointIndex>Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Long Term Effects of Raloxifene Treatment on Bone Quality</TitleDisplay><PatientSegmentTerms><PatientSegment>Menopause - Subjects with Bone Disorders</PatientSegment><PatientSegment>Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects</PatientSegment><PatientSegment>Osteoporosis - Subjects with Postmenopausal Osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with Primary Osteoporosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>7</NumberOfSites></Trial><Trial Id="3511"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin sensitizer</Action><Action>PPAR alpha agonist</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihyperlipidemic agent</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Bristol-Myers Squibb Co</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Argentina</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Puerto Rico</Country><Country>South Africa</Country><Country>Sweden</Country><Country>Brazil</Country><Country>Canada</Country><Country>France</Country><Country>Netherlands</Country><Country>US</Country><Country>Mexico</Country><Country>UK</Country><Country>Australia</Country><Country>Italy</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2006-06-01T00:00:00Z</DateEnd><DateStart>2002-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CV168-006</Identifier><Identifier>NCT00240383</Identifier><Identifier>PPAR</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>muraglitazar alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1260</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A randomized, double-blind, dose-ranging, dose comparison-controlled trial to determine the safety and efficacy of muraglitazar in subjects with type 2 diabetes.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Non-HDL levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PPAR: Dose Ranging Study With LT, Monotherapy, PPAR</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>268</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>